T-VEC and checkpoint therapy for melanoma

Source: eCancer TV, June 2017

Prof Andtbacka speaks with ecancer at ASCO 2017 about results from the 264 trial, the first trial combining the oncolytic virus T-VEC with checkpoint inhibition to treat melanoma.

He describes a response rate of 38% among the 98 patients receiving T-VEC and ipilimumab, with overall survival data yet to mature.

Adverse events associated with T-VEC compared to ipilimumab monotherapy as a control include a higher rate of fatigue and chills, with 28% of patients have a grade ?3 adverse event compared to 18%.

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories